SCHEMBL1234019

SCHEMBL1234019

CC(F)CN

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15688606 1.00
SCHEMBL16395565 1.00
Hydrochloric Acid SCHEMBL25214533 0.96
Hydrochloric Acid SCHEMBL16395482 0.96
Hydrochloric Acid SCHEMBL11635122 0.96
SCHEMBL14081835 0.72
SCHEMBL21846682 0.72
SCHEMBL24907240 0.72
SCHEMBL20385283 0.72
SCHEMBL18627013 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111727185-A Substituted N-heterocyclyl-and N-heteroaryltetrahydropyrimidines and their salts and their use as herbicidal active substances 拜耳公司 2020-09-29 CN claimed
US-12503475-B2 Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists CENTESSA PHARMACEUTICALS (UK) LIMITED (GB) 2025-12-23 US disclosed
US-20240027902-A1 CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2024-01-25 US disclosed
CN-117209393-A Preparation method of aromatic cyclopropyl formamide 泓博智源(开原)药业有限公司 2023-12-12 CN disclosed
US-20230365511-A1 Antiviral Pyrazolopiridinone Compounds NOVARTIS AG (CH) 2023-11-16 US disclosed
US-20230305393-A1 RESIST COMPOSITION AND PATTERN FORMING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-09-28 US disclosed
US-20230305394-A1 RESIST COMPOSITION AND PATTERN FORMING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-09-28 US disclosed
US-20230271973-A1 BICYCLIC-HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS CENTESSA PHARMACEUTICALS (OREXIA) LIMITED (GB) 2023-08-31 US disclosed
US-20230271973-A1 BICYCLIC-HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS CENTESSA PHARMACEUTICALS (OREXIA) LIMITED (GB) 2023-08-31 US disclosed
CN-116583502-A Bicyclic-heterocyclic derivatives and their use as orexin-2 receptor agonists 欧瑞夏治疗有限公司 2023-08-11 CN disclosed
US-20120171245-A1 INHIBITORS OF INFLUENZA VIRUSES REPLICATION VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-05 US disclosed
WO-2012062703-A1 METHOD FOR PREPARING 2,2-DIFLUOROETHYLAMINE STARTING FROM PROP-2-EN-1-AMINE BAYER CROPSCIENCE AG (DE) 2012-05-18 WO disclosed
EP-2431377-A1 Modified L-nucleic acids Noxxon Pharma AG (DE) 2012-03-21 EP disclosed
WO-2011069994-A1 METHOD FOR PRODUCING 2,2-DIFLUOROETHYLAMINE AND SALTS THEREOF, STARTING WITH DIFLUOROACETONE NITRILE BAYER CROPSCIENCE AG (DE) 2011-06-16 WO disclosed
WO-2011042376-A2 METHOD FOR PRODUCING 2,2-DIFLUOROETHYLAMINE BY HYDROGENATING 1,1-DIFLUORO-2-NITROETHANE BAYER CROPSCIENCE AG (DE) 2011-04-14 WO disclosed
JP-2011026260-A PROTECTED 2-FLUOROPROPYLAMINE HAVING LEAVING GROUP AT 3-POSITION OR PROTECTED N-ALKYL-2-FLUOROPROPYLAMINE HAVING LEAVING GROUP AT 3-POSITION CENTRAL GLASS CO LTD 2011-02-10 JP disclosed
WO-2011013635-A1 PROTECTED 2-FLUOROPROPYLAMINE HAVING LEAVING GROUP AT 3-POSITION OR PROTECTED N-ALKYL-2-FLUOROPROPYLAMINE HAVING LEAVING GROUP AT 3-POSITION セントラル硝子株式会社 (JP) 2011-02-03 WO disclosed
US-7781396-B2 Peptides directed for diagnosis and treatment of amyloid-associated disease TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) 2010-08-24 US disclosed
WO-2010022125-A1 ETHYNYL-SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS SCHERING CORPORATION (US) 2010-02-25 WO disclosed
WO-2009036901-A1 METHOD FOR PRODUCING 2,2-DIFLUOROETHYLAMINE DERIVATIVES BY IMINE HYDROGENATION BAYER CROPSCIENCE AG (DE) 2009-03-26 WO disclosed